SVB Leerink reiterated coverage on Aldeyra Therapeutics with a new price target

12/21/21 5:24:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

SVB Leerink reiterated coverage of Aldeyra Therapeutics with a rating of Outperform and set a new price target of $15.00 from $24.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALDX

Date	Price Target	Rating	Analyst
4/3/2024	$10.00	Perform → Outperform	Oppenheimer
4/2/2024	$10.00	Buy	H.C. Wainwright
4/27/2022	$15.00	Buy	H.C. Wainwright
12/21/2021	$25.00 → $21.00	Buy	Citigroup
12/21/2021	$24.00 → $15.00	Outperform	SVB Leerink